Seres Therapeutics
MCRB
77 hedge funds and large institutions have $60.1M invested in Seres Therapeutics in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 25 closing their positions.
99% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $607K
20% more capital invested
Capital invested by funds: $50M → $60.1M (+$10M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 2.28% → 2.08% (-0.2%)
17% less funds holding
Funds holding: 93 → 77 (-16)
41% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 27
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$640K |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
+$400K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$379K |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$285K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.24M |
| 2 |
Millennium Management
New York
|
-$766K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$727K |
| 4 |
Jane Street
New York
|
-$696K |
| 5 |
Goldman Sachs
New York
|
-$662K |
MCRB Hedge Fund Activity: Q3 2024 in Review
77 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2024, worth a combined $60.1M — up 20% from $50M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MCRB and 9 opened new positions — a net loss of 16 holders — while 27 trimmed existing stakes and 16 added.
The largest buyer was Morgan Stanley, adding an estimated $640K. The largest seller was Tang Capital Management, cutting an estimated $2.24M.
- 77 institutional investors held Seres Therapeutics (MCRB) as of Q3 2024, down from 93 in Q2 2024.
- Funds reported $60.1M of Seres Therapeutics stock for Q3 2024, up 20% quarter-over-quarter.
- 9 funds opened new Seres Therapeutics positions in Q3 2024 and 25 closed out, a net change of -16 holders.
- The largest Seres Therapeutics buyer in Q3 2024 was Morgan Stanley, an estimated $640K added.
- The largest Seres Therapeutics seller in Q3 2024 was Tang Capital Management, an estimated $2.24M sold.
Based on aggregated 13F filings for Q3 2024.